The global direct oral anticoagulants (DOACs) market was estimated at US$ 43.9 billion in 2023 and is projected to grow to US$ 102.36 billion by 2034, rising at a compound annual growth rate (CAGR) of 8% from 2024 to 2034. DOACs are in high demand due to their use as anticoagulation in various cardiovascular diseases.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5287
Direct Oral Anticoagulants (DOACs) have quickly become a preferred alternative to the traditional anticoagulant treatment involving vitamin K antagonists. These medications are used to prevent and treat various cardiovascular disorders and have become particularly popular in managing thromboembolic conditions. DOACs offer patients and healthcare providers safer, more convenient, and effective treatment options. However, as their use increases, clinicians face more complex decisions regarding the appropriate drugs, treatment duration, and specific patient considerations.
In May 2023, VarmX, a biotech company focused on developing new ways to reverse anticoagulation, raised an additional €30 million in a Series B2 funding round.
In November 2022, the adoption of anticoagulants increased significantly, with around 460,000 new patients starting treatment since January 2022. This led to over 24 million prescriptions being written, helping prevent an estimated 17,000 strokes and 4,000 deaths.
Despite advances in prevention and treatment, CVDs remain a leading cause of death worldwide. In the U.S., non-communicable diseases (NCDs), especially CVDs, place a heavy burden on the healthcare system. The CDC reports that NCDs cost the U.S. economy over $216 billion in healthcare expenses and result in $147 billion in lost productivity due to workplace absenteeism. The rising incidence of thrombotic events in CVDs, which can be mitigated with anticoagulants, is driving the demand for DOACs. These drugs are widely used for stroke prevention in atrial fibrillation, treating acute coronary syndrome, and preventing future cardiovascular events.
While DOACs offer significant benefits, they also come with potential side effects. Like all medications, DOACs can cause adverse reactions in some patients, with bleeding being one of the most serious risks. Major bleeding events are a particular concern, and managing these risks remains a challenge for healthcare providers.
In 2023, North America dominated the DOACs market, driven by advanced healthcare infrastructure, government support, and substantial investments from pharmaceutical companies. The U.S. and Canada are the key contributors to this market growth.
The U.S. alone has a high incidence of cardiovascular diseases, with a growing emphasis on tackling these health challenges. By 2050, the cost of healthcare for cardiovascular conditions in the U.S. is expected to more than triple, significantly impacting the economy and healthcare spending.
Asia Pacific is expected to experience the fastest market growth during the forecast period. The region’s large population offers a massive consumer base and skilled workforce, driving the growth of the DOACs market. Key factors include increased healthcare investments, rising innovation, and a growing prevalence of CVDs in countries like China and India.
China currently has over 330 million CVD patients, with a significant portion suffering from hypertension, coronary heart disease, heart failure, and atrial fibrillation. Similarly, in India, a major heart health awareness campaign launched in 2023 aims to treat 75 million people with diabetes and hypertension by 2025, marking a significant step in addressing CVD risks.
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/direct-oral-anticoagulants-doacs-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5287
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Visit Dental Specifics: https://www.towardsdental.com
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Vein Finder Market Growth and Forecast (2024 - 2032) The global vein finder market is projected to expand from USD… Read More
Bone Densitometer Market Overview Growth, Trends and Future Projections The global bone densitometer market was valued at USD 308.33 million… Read More
Global Market for Autoimmune Hepatitis Diagnosis and Treatment Projected Growth and Trends The global market for autoimmune hepatitis diagnosis and… Read More
Hemato-Oncology Testing Market Growth and Key Players The global hemato-oncology testing market was valued at $3.17 billion in 2023 and… Read More
Synovial Sarcoma Treatment Market Insights The synovial sarcoma treatment market was valued at USD 822.74 million in 2023 and is… Read More
Chronic Lower Back Pain Market Growth, Future Trends and Forecast The chronic lower back pain market was valued at $2.46… Read More